$ZIVO
Zivo Bioscience, Inc.

2023 Q2 Form 10-Q Financial Statement

#000165495423006097 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $4.050K $0.00 $0.00
YoY Change
Cost Of Revenue $701.00 $0.00
YoY Change
Gross Profit $3.349K $0.00
YoY Change
Gross Profit Margin 82.69%
Selling, General & Admin $1.385M $1.568M $1.347M
YoY Change -15.0% 16.46% -6.27%
% of Gross Profit 41358.61%
Research & Development $442.1K $401.8K $679.8K
YoY Change 0.93% -40.89% 5.11%
% of Gross Profit 13201.34%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.827M $1.970M $2.027M
YoY Change -11.63% -2.78% -2.74%
Operating Profit -$1.824M -$1.970M -$2.027M
YoY Change -11.79% -2.78%
Interest Expense $31.79K $2.968K $1.805K
YoY Change 650.19% 64.43% -92.62%
% of Operating Profit
Other Income/Expense, Net $246.7K $2.968K -$1.805K
YoY Change 5721.28% -264.43% -98.67%
Pretax Income -$2.071M -$1.973M -$2.028M
YoY Change -0.06% -2.72% -8.59%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.071M -$1.973M -$2.028M
YoY Change -0.06% -2.72% -8.59%
Net Earnings / Revenue -51125.23%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.22 -$0.21 -$215.3K
COMMON SHARES
Basic Shares Outstanding 9.420M shares 9.420M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.07K $208.6K $6.599M
YoY Change -99.59% -96.84% 2745.12%
Cash & Equivalents $21.07K $208.6K $6.599M
Short-Term Investments
Other Short-Term Assets $509.0K $719.6K $855.3K
YoY Change -1.57% -15.86% 277.68%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $530.1K $928.2K $7.454M
YoY Change -90.54% -87.55% 1526.21%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $180.3K $199.8K $233.9K
YoY Change -31.66% -14.6% 22.78%
TOTAL ASSETS
Total Short-Term Assets $530.1K $928.2K $7.454M
Total Long-Term Assets $180.3K $199.8K $233.9K
Total Assets $710.3K $1.128M $7.688M
YoY Change -87.89% -85.33% 1084.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.273M $670.3K $520.4K
YoY Change 212.24% 28.81% -70.01%
Accrued Expenses $681.9K $563.7K $301.8K
YoY Change 7.92% 86.77% -89.47%
Deferred Revenue
YoY Change
Short-Term Debt $1.112M $538.3K $558.8K
YoY Change 218.36% -3.66% 252.2%
Long-Term Debt Due $240.0K $240.0K $240.0K
YoY Change 0.0% 0.0% -95.37%
Total Short-Term Liabilities $3.804M $2.791M $2.959M
YoY Change 41.05% -5.71% -75.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $50.92K $79.03K $144.1K
YoY Change -67.57% -45.17% 1351.56%
Total Long-Term Liabilities $50.92K $79.03K $144.1K
YoY Change -67.57% -45.17% 9.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.804M $2.791M $2.959M
Total Long-Term Liabilities $50.92K $79.03K $144.1K
Total Liabilities $3.855M $2.870M $3.104M
YoY Change 35.07% -7.54% -74.29%
SHAREHOLDERS EQUITY
Retained Earnings -$119.8M -$117.8M
YoY Change 6.7%
Common Stock $9.420K $9.420K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.145M -$1.742M $4.585M
YoY Change
Total Liabilities & Shareholders Equity $710.3K $1.128M $7.688M
YoY Change -87.89% -85.33% 1084.83%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$2.071M -$1.973M -$2.028M
YoY Change -0.06% -2.72% -8.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$985.7K -$2.129M -$2.862M
YoY Change -24.51% -25.6% 172.02%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 798.1K $538.3K $558.8K
YoY Change -480.9% -3.66% -51.25%
NET CHANGE
Cash From Operating Activities -985.7K -$2.129M -$2.862M
Cash From Investing Activities 0.000 $0.00 $0.00
Cash From Financing Activities 798.1K $538.3K $558.8K
Net Change In Cash -187.5K -$1.591M -$2.303M
YoY Change -87.62% -30.93% -2547.96%
FREE CASH FLOW
Cash From Operating Activities -$985.7K -$2.129M -$2.862M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001101026
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
9419660 shares
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40449
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Zivo Bioscience, Inc.
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0699977
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
21 East Long Lake Road, Ste. 100
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bloomfield Hills
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48304
CY2023Q1 dei City Area Code
CityAreaCode
248
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
452-9866
CY2023Q1 dei Trading Symbol
TradingSymbol
ZIVO
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9419660 shares
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
208601 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1799263 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
719613 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
102416 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
928214 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1901679 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
167692 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
189282 usd
CY2023Q1 us-gaap Security Deposit
SecurityDeposit
32058 usd
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
32058 usd
CY2023Q1 us-gaap Other Assets
OtherAssets
199750 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
221340 usd
CY2023Q1 us-gaap Assets
Assets
1127964 usd
CY2022Q4 us-gaap Assets
Assets
2123019 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
670280 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
490670 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
103076 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
99259 usd
CY2023Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
240000 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
240000 usd
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
432150 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
525904 usd
CY2023Q1 zivo Deferred Rd Obligations Participation Agreements Related Parties
DeferredRDObligationsParticipationAgreementsRelatedParties
144153 usd
CY2022Q4 zivo Deferred Rd Obligations Participation Agreements Related Parties
DeferredRDObligationsParticipationAgreementsRelatedParties
175427 usd
CY2023Q1 us-gaap Loans Payable
LoansPayable
538311 usd
CY2022Q4 us-gaap Loans Payable
LoansPayable
0 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
98878 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
98286 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
563745 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
398176 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2790593 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2027722 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
79033 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105919 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
79033 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
105919 usd
CY2023Q1 us-gaap Liabilities
Liabilities
2869626 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2133641 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
150000000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9419660 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9419660 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
9420 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
9420 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
116026590 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
115784488 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117777672 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115804530 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1741662 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10622 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1127964 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2123019 usd
CY2023Q1 us-gaap Results Of Operations Revenue Other
ResultsOfOperationsRevenueOther
0 usd
CY2022Q1 us-gaap Results Of Operations Revenue Other
ResultsOfOperationsRevenueOther
0 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
CY2022Q1 us-gaap Revenues
Revenues
0 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1568377 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1346742 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
401797 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
679773 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1970174 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
2026515 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1970174 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2026515 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
2968 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
1805 usd
CY2023Q1 us-gaap Other Expenses
OtherExpenses
2968 usd
CY2022Q1 us-gaap Other Expenses
OtherExpenses
1805 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1973142 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2028320 usd
CY2023Q1 zivo Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.21
CY2022Q1 zivo Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.22
CY2023Q1 zivo Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
9419660 shares
CY2022Q1 zivo Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
9419660 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6042209 usd
CY2022Q1 zivo Employee And Director Equity Based Compensaton
EmployeeAndDirectorEquityBasedCompensaton
570629 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2028320 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4584518 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10622 usd
CY2023Q1 zivo Employee And Director Equity Based Compensaton
EmployeeAndDirectorEquityBasedCompensaton
242102 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1973142 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1741662 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
1973142 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
2028320 usd
CY2023Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
21590 usd
CY2022Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
21197 usd
CY2023Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
242102 usd
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
570629 usd
CY2023Q1 zivo Amortization Of Deferred Rd Obligations Participation Agreements
AmortizationOfDeferredRDObligationsParticipationAgreements
125028 usd
CY2022Q1 zivo Amortization Of Deferred Rd Obligations Participation Agreements
AmortizationOfDeferredRDObligationsParticipationAgreements
136848 usd
CY2023Q1 zivo Increase In Security Deposits
IncreaseInSecurityDeposits
0 usd
CY2022Q1 zivo Increase In Security Deposits
IncreaseInSecurityDeposits
-29058 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
617197 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
797179 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
179610 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-133966 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-23069 usd
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
185 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
166161 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-328289 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2128973 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2861649 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
605600 usd
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
628600 usd
CY2023Q1 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
67289 usd
CY2022Q1 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
69844 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
538311 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
558756 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1590662 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2302893 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1799263 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8901875 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
208601 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6598982 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
2377 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1213 usd
CY2023Q1 zivo Accumulated Deficit
AccumulatedDeficit
117777672 usd
CY2023Q1 zivo New Accounting Standards
NewAccountingStandards
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>NOTE 2 -NEW ACCOUNTING STANDARDS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. The Company adopted ASU 2020-06 effective January 1, 2023, using the modified retrospective approach. The adoption of AASU 2020-06 did not have an impact on any amounts recorded the Company's condensed consolidated financial statements. In addition, the adoption requires the use of the if-converted method for all convertible notes in the diluted net income (loss) per share calculation and the inclusion of the effect of potential share settlement of the convertible notes, if the effect is more dilutive. There was no impact to diluted earnings per share for the three months ended March 31, 2023, as the convertible debentures were not in the money during the period.</p>
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
27236 usd
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
26112 usd
CY2023Q1 zivo Operating Lease Weighted Average Remaining Lease Term
OperatingLeaseWeightedAverageRemainingLeaseTerm
P1Y8M15D
CY2022 zivo Operating Lease Weighted Average Remaining Lease Term
OperatingLeaseWeightedAverageRemainingLeaseTerm
P1Y11M8D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1100 pure
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1100 pure
CY2023Q1 zivo Cash Paid For Amounts Included In The Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
28145 usd
CY2022Q1 zivo Cash Paid For Amounts Included In The Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
5600 usd
CY2023Q1 zivo Non Cash Investment In Rou Asset
NonCashInvestmentInRouAsset
0 usd
CY2022Q1 zivo Non Cash Investment In Rou Asset
NonCashInvestmentInRouAsset
195804 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
88063 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
112407 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
200471 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18361 usd
CY2023Q1 zivo Present Value Of Future Minimum Lease Payment Sale Leaseback Transactions
PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions
182110 usd
CY2023Q1 zivo Operating Lease Liability Noncurrent1
OperatingLeaseLiabilityNoncurrent1
79033 usd
CY2023Q1 us-gaap Notes Payable
NotesPayable
605600 usd
CY2023Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.084 pure
CY2023Q1 us-gaap Debt Instrument Periodic Payment Interest
DebtInstrumentPeriodicPaymentInterest
69666 usd
CY2023Q1 us-gaap Loans Payable
LoansPayable
538311 usd
CY2023Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
125030 usd
CY2022Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
136848 usd
CY2023Q1 zivo Amortization Amount Attributable To Related Parties
AmortizationAmountAttributableToRelatedParties
31274 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 zivo Subscription Agreement Decription
SubscriptionAgreementDecription
pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Subscriber a 10% promissory note with a principal amount of $1 million (the “Note”) and a warrant (the “Warrant”) to purchase 390,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) at an exercise price of $2.91
CY2023Q2 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.10 pure

Files In Submission

Name View Source Status
0001654954-23-006097-index-headers.html Edgar Link pending
0001654954-23-006097-index.html Edgar Link pending
0001654954-23-006097.txt Edgar Link pending
0001654954-23-006097-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zivo-20230331.xsd Edgar Link pending
zivo_10q.htm Edgar Link pending
zivo_ex311.htm Edgar Link pending
zivo_ex312.htm Edgar Link pending
zivo_ex321.htm Edgar Link pending
zivo_ex322.htm Edgar Link pending
zivo-20230331_pre.xml Edgar Link unprocessable
zivo-20230331_cal.xml Edgar Link unprocessable
zivo-20230331_def.xml Edgar Link unprocessable
zivo-20230331_lab.xml Edgar Link unprocessable
zivo_10q_htm.xml Edgar Link completed